TRexBio prices IPO at $14 per share on Nasdaq

TRexBio has priced its initial public offering at 14 dollars per share on the Nasdaq exchange. Simultaneously, Retension Pharmaceuticals has priced its own IPO at 12 dollars per share on the Nasdaq. Both companies have finalized these pricing details for their respective market debuts on the exchange. These financial moves mark the official pricing phase for both TRexBio and Retension Pharmaceuticals as they prepare to enter the public trading environment on the Nasdaq platform.